Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

References

• PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet. 1998;352(9124):257–263. doi:10.1016/S0140-6736(98)06341-7
   PubMed Web of Science ®Google Scholar
• Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall- cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–910. doi:10.1136/bmj.311.7010.899
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360.
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7(9):719–727.
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–5051.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42.
   PubMed Web of Science ®Google Scholar
• Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non–small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2009;28:29–34.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95(19):1453–1461.
   PubMed Web of Science ®Google Scholar
• Waller D, Peaker MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26(1):173–182. doi:10.1016/j.ejcts.2004.03.041
   PubMed Web of Science ®Google Scholar
• Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;2(3):CD011430.
   Google Scholar
• Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol. 2010;5(2):220–228. doi:10.1097/JTO.0b013e3181c814e7
   PubMed Web of Science ®Google Scholar
• Novello S, Torri V, Grohe C, et al. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. Ann Oncol. 2022;33(1):57–66. doi:10.1016/j.annonc.2021.09.017
   PubMed Web of Science ®Google Scholar
• Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-uracil. Accessed January 10, 2022.
   Google Scholar
• Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23(22):4999–5006. doi:10.1200/JCO.2005.09.017
   PubMed Web of Science ®Google Scholar
• Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350(17):1713–1721. doi:10.1056/NEJMoa032792
   PubMed Web of Science ®Google Scholar
• Ichinose Y, Genka K, Koike T, et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst. 2003;95(8):605–610. doi:10.1093/jnci/95.8.605
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Ando M, Maemondo M, et al. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Oncologist. 2015;20(3):307–315. doi:10.1634/theoncologist.2014-0285
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6:863–873. doi:10.1016/S2213-2600(18)30277-7
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–148. doi:10.1016/S1470-2045(17)30729-5
   PubMed Web of Science ®Google Scholar
• Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIa (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713–722. doi:10.1200/JCO.20.01820
   PubMed Web of Science ®Google Scholar
• He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021;Sep(9):1021–1029.
   Web of Science ®Google Scholar
• Tada H, Mitsudomi T, Misumi T, et al. Randomized Phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT). J Clin Oncol. 2021;40:JCO2101729.
   Web of Science ®Google Scholar
• Ng TL, Camidge DR. Lung cancer’s real adjuvant EGFR targeted therapy questions. Lancet Oncol. 2018;19(1):15–17.
   PubMed Web of Science ®Google Scholar
• Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. NEJM. 2020;383(18):1711–1723.
   PubMed Web of Science ®Google Scholar
• Gyawali B, West H. Lessons from ADAURA on adjuvant cancer drug trials: evidence, ethics, and economics. J Clin Oncol. 2021;39(3):175–177.
   PubMed Web of Science ®Google Scholar
• Uprety D. Osimertinib should not yet be considered the standard of care for EGFR-mutant NSCLC in the adjuvant setting. J Thorac Oncol. 2021;16(3):371–374.
   PubMed Web of Science ®Google Scholar
• Wu YL, John T, Grohe C, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-Mutated NSCLC. J Thorac Oncol. 2021;17(3):423–433.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Lacas B, Le Teuff G, et al. Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2017;35(18):2018–2027.
   PubMed Web of Science ®Google Scholar
• Liu SY, Bao H, Wang Q, et al. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. 2021;12(1):6450.
   PubMed Web of Science ®Google Scholar
• Koch AL, Vellanki PJ, Drezner N, et al. FDA approval summary: osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative project orbis review. Clin Cancer Res. 2021;27(24):6638–6643.
   PubMed Web of Science ®Google Scholar
• Katz A, Saad ED. CALGB 9633: an underpowered trial with a methodologically questionable conclusion. J Clin Oncol. 2009;27(13):2300–2301.
   PubMed Web of Science ®Google Scholar